Immuneering is moving forward in its Phase 3 atebimetinib trial and is on track to dose the first patient. The company has secured alignment with both the FDA and EMA for this significant milestone. This progress marks a key step in the development of atebimetinib and signifies the company's dedication to advancing treatment options in the medical field.